Karin L. Walker - Oct 20, 2021 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Signature
/s/ Michael Malecek, as Attorney in Fact for Karin L. Walker
Stock symbol
PRTA
Transactions as of
Oct 20, 2021
Transactions value $
-$995,593
Form type
4
Date filed
10/22/2021, 05:53 PM
Previous filing
Jun 17, 2021
Next filing
Nov 26, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTA Ordinary Shares, par value $0.01 per share Options Exercise $301K +20K $15.04* 20K Oct 20, 2021 Direct
transaction PRTA Ordinary Shares, par value $0.01 per share Options Exercise $89.4K +3K +15% $29.81 23K Oct 20, 2021 Direct
transaction PRTA Ordinary Shares, par value $0.01 per share Sale -$1.15M -19.1K -83.11% $60.00 3.89K Oct 20, 2021 Direct F1, F2
transaction PRTA Ordinary Shares, par value $0.01 per share Sale -$104K -1.7K -43.76% $60.91 2.19K Oct 20, 2021 Direct F1, F3
transaction PRTA Ordinary Shares, par value $0.01 per share Sale -$135K -2.19K -100% $61.94 0 Oct 20, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRTA Stock Option (right to buy) Options Exercise $0 -20K -18.18% $0.00 90K Oct 20, 2021 Ordinary Shares 20K $15.04 Direct F5
transaction PRTA Stock Option (right to buy) Options Exercise $0 -3K -100% $0.00* 0 Oct 20, 2021 Ordinary Shares 3K $29.81 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $59.71 to $60.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The transaction was executed in multiple trades in prices ranging from $60.75 to $61.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 The transaction was executed in multiple trades in prices ranging from $61.84 to $62.22, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5 The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
F6 The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 4, 2015, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.